RGLS vs. BCRX, LGND, FOLD, CLDX, MNKD, NVAX, DVAX, INVA, OPK, and GERN
Should you be buying Regulus Therapeutics stock or one of its competitors? The main competitors of Regulus Therapeutics include BioCryst Pharmaceuticals (BCRX), Ligand Pharmaceuticals (LGND), Amicus Therapeutics (FOLD), Celldex Therapeutics (CLDX), MannKind (MNKD), Novavax (NVAX), Dynavax Technologies (DVAX), Innoviva (INVA), OPKO Health (OPK), and Geron (GERN). These companies are all part of the "biotechnology" industry.
Regulus Therapeutics vs.
BioCryst Pharmaceuticals (NASDAQ:BCRX) and Regulus Therapeutics (NASDAQ:RGLS) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, profitability, risk, community ranking, dividends, media sentiment, institutional ownership and valuation.
In the previous week, BioCryst Pharmaceuticals had 7 more articles in the media than Regulus Therapeutics. MarketBeat recorded 11 mentions for BioCryst Pharmaceuticals and 4 mentions for Regulus Therapeutics. BioCryst Pharmaceuticals' average media sentiment score of 1.04 beat Regulus Therapeutics' score of 0.90 indicating that BioCryst Pharmaceuticals is being referred to more favorably in the media.
85.9% of BioCryst Pharmaceuticals shares are held by institutional investors. Comparatively, 92.4% of Regulus Therapeutics shares are held by institutional investors. 4.8% of BioCryst Pharmaceuticals shares are held by company insiders. Comparatively, 4.4% of Regulus Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Regulus Therapeutics has lower revenue, but higher earnings than BioCryst Pharmaceuticals. BioCryst Pharmaceuticals is trading at a lower price-to-earnings ratio than Regulus Therapeutics, indicating that it is currently the more affordable of the two stocks.
BioCryst Pharmaceuticals has a beta of 1.08, suggesting that its share price is 8% more volatile than the S&P 500. Comparatively, Regulus Therapeutics has a beta of 0.49, suggesting that its share price is 51% less volatile than the S&P 500.
BioCryst Pharmaceuticals received 4 more outperform votes than Regulus Therapeutics when rated by MarketBeat users. Likewise, 67.12% of users gave BioCryst Pharmaceuticals an outperform vote while only 63.33% of users gave Regulus Therapeutics an outperform vote.
BioCryst Pharmaceuticals currently has a consensus price target of $16.56, suggesting a potential upside of 60.27%. Regulus Therapeutics has a consensus price target of $8.50, suggesting a potential upside of 6.92%. Given BioCryst Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts plainly believe BioCryst Pharmaceuticals is more favorable than Regulus Therapeutics.
Regulus Therapeutics has a net margin of 0.00% compared to BioCryst Pharmaceuticals' net margin of -30.01%. BioCryst Pharmaceuticals' return on equity of 0.00% beat Regulus Therapeutics' return on equity.
Summary
BioCryst Pharmaceuticals beats Regulus Therapeutics on 13 of the 17 factors compared between the two stocks.
Get Regulus Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for RGLS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Regulus Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:RGLS) was last updated on 5/21/2025 by MarketBeat.com Staff
Buy RGLS Stock Free RGLS Stock Alerts